AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in biopharmaceutical business focusing on the research, development and commercialization of prescription medicines. Co. focuses on disease areas that include Oncology; BioPharmaceuticals; Rare Disease; and Other Medicines and COVID-19. Key marketed products within the area of oncology include among other, Tagrisso (osimertinib) for lung cancer and Lynparza (olaparib) for ovarian cancer. Key marketed products within the area of Other Medicines and COVID-19 include among other, Synagis (palivizumab) for respiratory syncytial virus; and Evusheld (tixagevimab co-packaged with cilgavimab) for COVID-19.